

## Editorial

# Entheses Ossification in Spondyloarthritis

**Maruotti N, Neve A and Cantatore FP\***

Rheumatology Clinic, Department of Medical and Surgical Sciences, University of Foggia Medical School, Foggia, Italy

**\*Corresponding author:** Francesco Paolo Cantatore, Rheumatology Clinic “Mario Carrozzo”, Ospedali Riuniti Hospital, Department of Medical and Surgical Sciences, University of Foggia Medical School, Viale Pinto, 11-71100 Foggia, Italy

**Received:** March 25, 2016; **Accepted:** March 28, 2016;**Published:** March 28, 2016

## Editorial

Spondyloarthritis (SpA) is a group of diseases including Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), reactive arthritis, inflammatory bowel diseases, and undifferentiated arthritis, characterized by several common genetic, clinical and radiological features. Important common clinical features are spinal inflammation, sacroiliitis, peripheral arthritis and enthesitis.

Above all entheses, the attachment sites of tendons, ligaments, joint capsules, fasciae or muscles to bones, responsible for the dissipation of mechanical stress and for myofascial stabilization, play a key role in SpA pathogenesis. In fact, there are increasing evidences that entheses are the primary target tissue for inflammation in SpA, responsible for a lot of symptoms, and for the numerous locations of pain in SpA patients [1].

In past years, enthesitis inflammation was believed to be involved in the destruction of the attachment of ligaments to bone, which in turn leads to reactive new bone formation [2]. Nevertheless, following evidences demonstrated that the sequence “inflammation-bone destruction-reactive osteoproliferation” was not acceptable. As demonstrated in murine studies both destruction and osteoproliferation occur simultaneously with inflammation and all process is driven by Tumor Necrosis Factor (TNF)- $\alpha$  [3-5]. Nevertheless, there are not studies that support this hypothesis in humans.

Even if cellular and molecular aspects of inflammation and bone destruction in SpA have been largely studied, very less is known concerning bone production. We know that it occurs by endochondral ossification; nevertheless factors involved in its induction and progression are not clear. In fact, human SpA ossification is not only a consequence of inflammation, but other processes are probably involved.

TNF- $\alpha$  is an inflammatory cytokine involved in the pathogenesis of these diseases as demonstrated by mononuclear infiltrates within the cartilage, and by TNF- $\alpha$  mRNA found in sacroiliac joints of patients affected by AS [6-8]. In consideration of the important role of TNF- $\alpha$  in the pathogenesis of these diseases, since the beginning of 2000, anti-TNF- $\alpha$  agents are increasingly used for the treatment of SpAs. Nevertheless, even if several studies reported the positive

control of clinical and biological inflammation and joint destruction, persistent ossification has been often seen in SpA patients treated with anti-TNF $\alpha$  [9-12]. Taken together, these data suggest that TNF- $\alpha$  could contribute to inflammation and bone resorption, but other pathogenic pathways are also involved in inducing SpA bone formation.

In fact, IL-17/IL-23 axis is considered to play a key role in SpA pathogenesis and their serum levels have been associated with disease activity in active AS patients [13,14]. On one hand over expression of IL-17 has been associated with synovial inflammation and joint destruction *in vivo* and, on the other hand, IL-17 deficiency or inhibition has been seen to reduce joint inflammation and damage [15,16]. Moreover, IL-23 plays a role in entheses inflammation and promotes IL-17 and IL-22 expression by enthesal resident cells in mice with collagen-antibody-induced arthritis (CAIA) [17]. Thus, IL-17 plays a role in SpA enthesitis and bone erosion, whereas IL-22 is involved in the new bone formation. In fact, IL-22 induces genes involved in bone formation, such as genes encoding Wnt family members, bone morphogenic proteins and alkaline phosphatase. Moreover, IL-22 is responsible for the activation *in vivo* of the signal transducer and activator of transcription 3 (STAT3), a transcription factor involved in inducing bone formation [18]. Thus, IL-17 and IL-22 are involved in inflammation, bone erosion and bone formation, and are considered new therapeutic targets in the treatment of SpA, as demonstrated by trials in AS and PsA, using secukinumab, a fully human anti-IL-17A monoclonal antibody [19, 20]. The preliminary data show positive results on symptomatology and inflammation, while long-term studies are necessary to demonstrate an effect on excess bone formation [21].

It is conceivable that even other factors are probably involved in SpA enthesal ossification. In fact, a role in bone formation and in ligament ossification in AS has been described for transforming growth factor- $\beta$  (TGF- $\beta$ ) and for chemokine (C-C motif) ligand 19 (CCL19) and 21 (CCL21) [22,23].

Other agents involved in bone formation are leptin and adiponectin [24,25]. These two molecules are adipokines produced by adipose tissue, responsible for controlling various physiological systems via an extensive network of communication both within adipose tissue and with other organs. If we consider that 45.8% of AS patients are at risk of occurrence of Metabolic Syndrome (MetS) versus 10.5% of healthy controls [26], and that adipokines play a regulatory role in MetS [27], it is hypothesizable that these molecules may be probably involved in SpA bone formation.

Another factor which probably plays a role in the pathogenesis of SpA is mechanical stress, as demonstrated by recent observations in murine studies [28].

Taken together, these observations underline the complexity of the mechanisms involved in SpA pathogenesis. Thus, TNF- $\alpha$ , IL-17 and IL-23 may be considered as components of a great molecular

cauldron, where they certainly play a key role, but where even other mechanisms, only in part known, influence important clinical aspects of SpA, such as enthesal ossification. Therefore, further research and clinical trials are needed to better determine these mechanisms and to identify the most appropriate therapeutic strategies.

## References

- Miceli-Richard C. Enthesitis: The clue to the pathogenesis of Spondyloarthritis? *Joint Bone Spine*. 2015; 82: 402-405.
- Ball J. The enthesopathy of ankylosing spondylitis. *Br J Rheumatol*. 1983; 22: 25-28.
- Alexopoulou L, Pasparakis M, Kollias G. A murine transmembrane Tumor Necrosis Factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. *Eur J Immunol*. 1997; 27: 2588-2592.
- Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. *Immunity*. 1999; 10: 387-398.
- Edwards CK 3rd, Bendele AM, Reznikov LI, Fantuzzi G, Chlipala ES, Li L, Moldawer LL, et al. Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor alpha. *Arthritis Rheum*. 2006; 54: 2872-2885.
- Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of Immunohistological and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. *Arthritis Rheum*. 1995; 38: 499-505.
- Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. *J Rheumatol*. 1997; 24: 518-523.
- Muche B, Bollow M, François RJ, Sieper J, Hamm B, Braun J. Anatomic structures involved in early- and latest age sacroiliitis in Spondyloarthritis: a detailed analysis by contrast enhanced magnetic resonance imaging. *Arthritis Rheum*. 2003; 48: 1374-1384.
- Van der Heijde D, Landewé R, Baraliakos X, Houben H, van Tubergen A, Williamson P, et al. Ankylosing spondylitis study for the evaluation of recombinant infliximab therapy study group: radiographic findings following two years of Infliximab therapy in patients with ankylosing spondylitis. *Arthritis Rheum*. 2008; 58: 3063-3070.
- Van der Heijde D, Landewé R, Einstein S, Ory P, Vosse D, Ni L. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. *Arthritis Rheum*. 2008; 58: 1324-1331.
- Van der Heijde D, Salonen D, Weissman BN, Landewé R, Maksymowych WP, Kupper H. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. *Arthritis Res Ther*. 2009; 11: R127.
- Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 years of treatment with the TNF-alpha antibody Infliximab. *Rheumatology*. 2007; 46:1450-1453.
- Xueyi L, Lina C, Zhenbiao W, Qing H, Qiang L, Zhu P. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF- $\alpha$  therapy. *J Clin Immunol*. 2013; 33: 151-161.
- Yeremenko N, Paramarta JE, Baeten D. The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of Spondyloarthritis. *Curr Opin Rheumatol*. 2014; 26: 361-370.
- Lubberts E, Joosten LA, van de Loo FA, Schwarzenberger P, Kolls J, van den Berg WB. Over expression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. *Inflamm Res*. 2002; 51: 102-104.
- Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. *Arthritis Rheum*. 2004; 50: 650-659.
- Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J. IL-23 induces spondyloarthropathy by acting on ROR- $\gamma$ t+ CD3+CD4-CD8- enthesal resident T cells. *Nat Med*. 2012; 18: 1069-1076.
- Nicolaidou V, Wong MM, Redpath AN, Ersek A, Baban DF, Williams LM. Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation. *PLoS One*. 2012; 7: e39871.
- Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2013; 382: 1705-1713.
- McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. *Ann Rheum Dis*. 2014; 73: 349-356.
- Rossini M, Viapiana O, Adami S, Idolazzi L, Fracassi E. Focal bone involvement in inflammatory arthritis: the role of IL17. *Rheumatol Int*. 2016; 36: 469-482.
- François RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. *Ann Rheum Dis*. 2006; 65: 713-720.
- Qin Y, He LD, Sheng ZJ, Yong MM, Sheng YS, Wei Dong X. Increased CCL19 and CCL21 levels promote fibroblast ossification in ankylosing spondylitis hip ligament tissue. *BMC Musculoskelet Disord*. 2014; 15: 316.
- Turner RT, Kalra SP, Wong CP, Philbrick KA, Lindenmaier LB, Boghossian S. Peripheral leptin regulates bone formation. *J Bone Miner Res*. 2013; 28: 22-34.
- Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL. Leptin directly regulates bone cell function in vitro and reduces bone fragility *in vivo*. *J Endocrinol*. 2002; 175: 405-415.
- Malesci D, Niglio A, Mennillo GA, Buono R, Valentini G, La Montagna G. High prevalence of metabolic syndrome in patients with ankylosing spondylitis. *Clin Rheumatol*. 2007; 26: 710-714.
- Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. *Ann N Y Acad Sci*. 2010; 1212: E1-1E19.
- Jacques P, Lambrecht S, Verheugen E, Pauwels E, Kollias G, Armaka M. Proof of concept: enthesitis and new bone formation in Spondyloarthritis are driven by mechanical strain and stromal cells. *Ann Rheum Dis*. 2014; 73: 437-445.